BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

CEO

Mr. Kenneth Mulvany

Pekerja

180

Negara

Luxembourg

ISIN

LU2355630455

WKN

000A3CTVP

Penyenaraian

STU

2XA.STU

0 Comments

Kongsi pendapat anda

FAQ

Berapakah harga saham Odyssey Acquisition. hari ini?▼

Harga semasa 2XA.STU ialah €0.57 EUR — telah meningkat sebanyak +7.2% dalam 24 jam yang lalu. Pantau prestasi harga saham Odyssey Acquisition. dengan lebih dekat pada carta.

Apakah simbol saham Odyssey Acquisition.?▼

Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa Boerse Stuttgart, saham Odyssey Acquisition. didagangkan di bawah simbol 2XA.STU.

Berapa ramai pekerja yang dimiliki oleh Odyssey Acquisition.?▼

Sehingga September 04, 2026, syarikat mempunyai 180 pekerja.

Odyssey Acquisition. terletak dalam sektor apa?▼

Odyssey Acquisition. beroperasi dalam sektor Kesihatan & Kesejahteraan.

Bilakah Odyssey Acquisition. menyiapkan split saham?▼

Odyssey Acquisition. tidak mempunyai sebarang split baru-baru ini.

Di manakah ibu pejabat Odyssey Acquisition.?▼

Ibu pejabat Odyssey Acquisition. terletak di London, Luxembourg.